Written by [author]. Reviewed by [reviewer].
Updated . How we research and review.
Short answer
What is Retatrutide?
Retatrutide is a lipidated synthetic peptide of 39 amino acids that binds three receptors: GIP, GLP-1 and glucagon.
It also appears in the literature as LY3437943, Triple G.
Read the full explainer: what is Retatrutide?What is in each Retatrutide vial?
| STRENGTH | FORM | PRICE | CERTIFICATE |
|---|---|---|---|
| 10mg | Lyophilised powder | A$128 | Pending |
| 20mg | Lyophilised powder | A$228 | Pending |
What has research on Retatrutide examined?
Retatrutide has been examined in randomized human trials: phase 2 trials in obesity and in type 2 diabetes, a phase 2a study in metabolic dysfunction-associated steatotic liver disease, and a phase 3 trial in type 2 diabetes (TRANSCEND-T2D-1, published 2026). Further phase 3 programmes (TRIUMPH, TRANSCEND) are described in design papers.
The table lists primary sources by year and model. Findings describe the study subjects, not this research vial.
What adverse events have studies of Retatrutide reported?
In phase 2 trials in obesity and type 2 diabetes and a phase 3 type 2 diabetes trial, the most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. Dose-dependent heart-rate increases peaked at 24 weeks (PMID 37366315, 37385280, 42250575). In phase 3, 2-5% on retatrutide stopped because of adverse events, versus 0% on placebo.
These findings describe the people or animals in each study. The sources list gives every PubMed record.
How do you reconstitute and store Retatrutide?
Store the sealed vial frozen (about -20 degrees Celsius), dry and away from light until it is reconstituted.
After reconstitution with a sterile solvent, keep the solution at 2 to 8 degrees Celsius and avoid repeated freezing and thawing. Record the solvent, volume and date on the vial label.
BAC Water is the usual laboratory solvent. Dilute acetic acid is an alternative for peptides that dissolve poorly in water. The reconstitution guide and storage guide cover laboratory handling.
| STATE | TEMPERATURE | NOTES |
|---|---|---|
| Sealed vial | -20 °C | Dry and dark. Keeps to the label date. |
| Reconstituted | 2 to 8 °C | Sterile technique. Avoid repeat freeze and thaw. |
| In transit | Cold pack | Refrigerate or freeze on arrival. |
Is Retatrutide legal to buy in Australia?
Retatrutide is not named in the Poisons Standard (June 2026 instrument). Source: the June 2026 Poisons Standard instrument (F2026L00633).
Retatrutide is not named on WADA's 2026 Prohibited List. WADA's S0 class covers any substance without government approval for human use, so Sport Integrity Australia is the body to confirm its status.
- POISONS STANDARD
- Not named
- WADA 2026
- Not named
- SALE TERMS
- Research use only
How fast does Retatrutide ship?
Orders placed before [cut-off] leave Western Australia the same business day with tracking, by [carrier]. Delivery estimates for each state are on the shipping page.
How does Retatrutide compare?
Retatrutide questions
Can I buy retatrutide in Australia?
Yes. Peptides Collective sells Retatrutide in Australia for laboratory research use only, at A$128 for 10mg and A$228 for 20mg, with a certificate for every batch. Retatrutide is not named in the Poisons Standard (June 2026 instrument).
When will retatrutide be available in Australia?
Yes. Peptides Collective sells Retatrutide in Australia for laboratory research use only, at A$128 for 10mg and A$228 for 20mg, with a certificate for every batch. Retatrutide is not named in the Poisons Standard (June 2026 instrument).
What adverse events have studies of retatrutide reported?
In phase 2 trials in obesity and type 2 diabetes and a phase 3 type 2 diabetes trial, the most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. Dose-dependent heart-rate increases peaked at 24 weeks (PMID 37366315, 37385280, 42250575). In phase 3, 2-5% on retatrutide stopped because of adverse events, versus 0% on placebo.
What is the difference between the 10mg and 20mg vials?
Only the amount of Retatrutide in the vial differs: 10mg, 20mg. Each strength has its own batch number and its own certificate.
Is retatrutide a peptide?
Yes. Retatrutide is a peptide of 39 amino acids.
Is retatrutide a prescription medicine in Australia?
Retatrutide is not named in the Poisons Standard (June 2026 instrument). Peptides Collective sells it for laboratory research use only.
Is retatrutide banned in sport?
Retatrutide is not named on WADA's 2026 Prohibited List. WADA's S0 class covers any substance without government approval for human use, so Sport Integrity Australia is the body to confirm its status.
What is the CAS number for retatrutide?
The CAS number for Retatrutide is 2381089-83-2. Its PubChem CID is 171390338.
How long does an unopened retatrutide vial keep?
A sealed vial of lyophilised powder keeps to the date on its label when stored frozen, dry and dark. Once reconstituted, keep the solution at 2 to 8 degrees Celsius and record the date on the label.
Does every retatrutide batch have a certificate?
Yes. Every Retatrutide batch is tested by [lab] before it goes on sale, and the certificate is published under the batch number printed on the vial. The current batch certificate is [pending].
Where is retatrutide shipped from?
Orders ship tracked from Western Australia. Orders placed before [cut-off] leave the same business day. Delivery estimates by state are on the shipping page.
What purity is the current retatrutide batch?
The current Retatrutide batch certificate is [pending]. When it is published, it reports purity by HPLC to three decimal places and confirms identity by mass spectrometry.
Sources
- 1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine, 2023. PMID 37366315.
- 2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England), 2023. PMID 37385280.
- 3. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024. PMID 38858523.
- 4. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 42250575.
- 5. The power of three: Retatrutide's role in modern obesity and diabetes therapy. European journal of pharmacology, 2024. PMID 39515565.
- 6. PubChem CID 171390338. National Library of Medicine.
- 7. Poisons Standard, June 2026 instrument (F2026L00633). Federal Register of Legislation.
- 8. World Anti-Doping Code, 2026 Prohibited List. WADA.
